No Data
Express News | Star market in vitro diagnostic company performance is showing a clear warming trend.
Innotek (688253): Steady increase in penetration rate, looking forward to increased volume in both domestic and overseas markets in the fourth quarter.
Event: On October 26, 2024, the company released the performance report for the third quarter of 2024. During the reporting period, the company achieved total operating income of 0.521 billion yuan (+87.05%) and net income attributable to the parent company of 0.245 billion yuan (+1.
Third Quarter Report 2024
Express News | Innotek: Net income in the third quarter increased by 320% year-on-year.
Innotek (688253): Accelerated expansion overseas further enhances the certainty of high performance growth.
The company has added another overseas respiratory tract detection registration certificate, further enriching the product lineup: The company has voluntarily disclosed an announcement about the recent qualifications obtained by the company and its subsidiaries, with its wholly-owned subsidiary Innotek (Tangshan) Biotechnology Co., Ltd. recently obtaining a new one.
Express News | Innotek: The subsidiary recently obtained four new product qualifications.
No Data
No Data